Engrail Therapeutics
Phase 1Engrail delivers transformational therapies that improve the lives of patients with devastating neurologic, neuropsychiatric, and neurodevelopmental disorders.
Founded
2019
Focus
Small Molecules
About
Engrail delivers transformational therapies that improve the lives of patients with devastating neurologic, neuropsychiatric, and neurodevelopmental disorders.
Funding History
2Total raised: $189M
Series B$157MF-Prime CapitalOct 15, 2023
Series A$32MPivotal Life SciencesOct 15, 2020
Company Info
TypePrivate
Founded2019
LocationSan Diego, United States
StagePhase 1
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile